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Prophylactic negative pressure wound therapy (NPWT) has emerged as a promising 
intervention in patients at high risk for surgical site infection (SSI). One such group is obese 
gravidae, a growing population worldwide who are at high risk for both cesarean delivery and 
SSI. Although the precise mechanism by which NPWT aids incisional wound healing is 
unclear, experimental evidence suggests that it reduces bacterial contamination, edema, 
and exudate, increases microvascular blood flow, promotes formation of granulation tissue 
and reduces lateral tensile and shear stress. Data on NPWT after cesarean have hitherto 
been limited to retrospective cohort and small pilot randomized trials (RCT). Whereas some 
studies demonstrated benefit in reducing SSI and other wound complications, they were 
limited by small sample sizes, selection bias and confounding.  
Hyldig et al. conducted a multicenter RCT comparing NPWT with the PICO™ device (n=432) 
to standard dressing (n=444) in obese (BMI≥ 30Kg/m2) women after cesarean delivery in 
five hospitals in Denmark (Hyldig et al. BJOG. 2018 (2018-RCT-21679)). The primary 
outcome, SSI within the first 30 days, was reduced by 50% from 9.2% with standard 
dressing to 4.6% with NPWT. NPWT also reduced wound exudates, with no impact on 
endometritis and wound dehiscence. In an accompanying trial-based economic evaluation, 
NPWT appeared to possibly be cost saving particularly for women with a BMI ≥35 kg/m2 
(Hyldig et al. BJOG. 2018 (2018-OG-21731)).  
These data are an important contribution to the evidence-base for the use of NPWT after 
cesarean delivery. The multicenter randomized design and sample size of over 800 patients 
are strengths of the study. Given that the current FDA-cleared prophylactic single-use NPWT 
devices cost between $200 (PICO™) and $500 (Prevena™) on average per unit, cost is an 
important consideration. The economic analysis presented here is a significant improvement 
upon the model based cost effectiveness analyses that were conducted prior to the 
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availability of RCT data on the efficacy of NPWT after cesarean delivery (Echebiri et al, 
Obstet Gynecol. 125(2):299–307; Tuffaha et al. J Surg Res 2015;195:612-2). However, 
while the sample size of over 800 is the largest to date, it remains modest. Moreover, the 
patient population of largely young obese Caucasian women without co-morbidities limits 
generalizability of the findings to other settings.  
So are we there yet? A meta-analysis of four small RCTs with sample sizes ranging from 87 
to 535) suggested that use of NPWT after cesarean delivery in high-risk patients significantly 
reduced the risk of SSI (pooled relative risk 0.55; 95% confidence interval 0.35, 0.87) (Yu et 
al. Am J Obstet Gynecol. 2018 Feb; 218 (2):200-210.e1). Together with data from the RCT 
by Hyldig et al., the evidence in support of NPWT after cesarean is increasing. However, the 
studies are clinically heterogeneous with small to moderate sample sizes and limited 
generalizability. Results of ongoing large multicenter RCTs in the United States and 
Australia enrolling more diverse patients will help clarify the role of NPWT after cesarean 
delivery (NCT03009110; ACTRN12615000286549). 
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